FWM
OVID icon

FFT Wealth Management’s Ovid Therapeutics OVID Stock Holding History

FFT Wealth Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-489,552
Closed -$377K – 171
2024
Q2 		$377K Buy
489,552
+75,530
+18% +$210K 0.03% 96
2024
Q1 		$1.26M Buy
414,022
+18,248
+5% +$61.1K 0.11% 53
2023
Q4 		$1.27M Buy
+395,774
New +$1.35M 0.11% 43

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FFT Wealth Management's OVID Position: Q3 2024 in Review

FFT Wealth Management sold out of Ovid Therapeutics (OVID) in Q3 2024, closing a stake of 489,552 shares — an estimated $377K sold.

FFT Wealth Management first reported a position in OVID in Q4 2023 and held it in 3 quarters. The position peaked at $1.27M in Q4 2023. 75 funds tracked by Wall St. Rank hold OVID as of Q3 2024.

  • FFT Wealth Management reported no remaining Ovid Therapeutics position as of Q3 2024 after selling out during the quarter.
  • FFT Wealth Management sold 489,552 Ovid Therapeutics shares in Q3 2024, an estimated $377K.
  • FFT Wealth Management first reported a position in Ovid Therapeutics in Q4 2023 and held it in 3 quarters.
  • FFT Wealth Management's Ovid Therapeutics position peaked at $1.27M in Q4 2023.
  • 75 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2024.

Based on FFT Wealth Management's 13F filing for Q3 2024, filed 12 Nov 2024.